- Home
- RDCM vs FHTX Comparison
RDCM vs FHTX Comparison
Compare RDCM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | FHTX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 111.1M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDCM | FHTX |
|---|---|---|
| Price | $10.16 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $14.00 | $4.17 |
| AVG Volume (30 Days) | 43.7K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.56 | $15.98 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.40 | $1.79 |
| 52 Week High | $16.74 | $7.61 |
Technical Indicators
Market Signals| Indicator | RDCM | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 25.12 |
| Support Level | $10.07 | $1.79 |
| Resistance Level | $10.48 | $5.27 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 43.86 | 61.43 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.